Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The name "Mango" refers to both a branded pharmaceutical product for men's health and the fruit *Mangifera indica*, which is utilized as a therapeutic dietary intervention. As a pharmaceutical, "Mango" is a brand of erectile dysfunction (ED) medication developed by Mangoceuticals, Inc., typically marketed through a telemedicine platform. As a nutraceutical intervention, mango fruit is rich in bioactive polyphenols, including gallotannins and mangiferin. Clinical research indicates that regular mango consumption can significantly increase insulin sensitivity and improve the disposition index in individuals with overweight or obesity and chronic low-grade inflammation, potentially through the activation of the Nrf2 antioxidant defense pathway. Additionally, mango has been studied as an adjuvant therapy for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, where it has demonstrated the ability to reduce pro-inflammatory biomarkers (such as IL-6 and TNF-α), decrease serum endotoxin levels, and modulate the gut microbiota to favor beneficial probiotic bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mango.